AKT1 and cancer: eATP (≥1000 μM) was found to inhibit mTOR via upstream blockade of phosphatidylinositol-3-OH kinase/protein kinase B (PI3K/AKT) and activation of AMP kinase (AMPK) in cancer cells [63].